CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy

The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.

Trial Details

NCT ID
NCT07779018
Phase
PHASE2
Sponsor
Liping Dou
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD22/CD19 CAR-T cell immunotherapy
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 1\. With the patient's consent and signed informed consent form, willing and able to comply with the planned visits, research treatments, laborator…
  • 3\. The possible high-risk factors for the patient's onset of the disease are as follows: 1) FISH confirmed high-grade B-cell lymphoma with double …
  • Patients who are not eligible for hematopoietic stem cell transplantation (HSCT) or who refuse HSCT.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →